NSGO Publication List

Peer reviewed  publications

13.01.2015

2015

Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial.

Floquet A1, Vergote I2, Colombo N3, Fiane B4, Monk BJ5, Reinthaller A6, Calvert P7, Herzog TJ8, Meier W9, Kim JW10, Del Campo JM11, Friedlander M12, Pisano C13, Isonishi S14, Crescenzo RJ15, Barrett C16, Wang K15, Mitrica I15, du Bois A17.

BACKGROUND:
Analysis of progression-free survival (PFS) as the primary endpoint in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments. PFS as assessed by local investigator (INV) was the primary endpoint of AGO-OVAR16, a randomized, double-blind trial of pazopanib maintenance therapy in AEOC. To confirm the robustness of the primary analysis, PFS was also evaluated by blinded independent central review (BICR).

METHODS:
Patients with histologically confirmed AEOC (N=940) were randomized 1:1 to receive pazopanib 800mg/day or placebo for up to 24months. Tumor response in the intent-to-treat population was evaluated by CT/MRI every 6months and analyzed per RECIST 1.0.

RESULTS:
Pazopanib prolonged PFS versus placebo by INV (median 17.9 vs 12.3months; hazard ratio [HR]=0.766, 95% confidence interval [CI]: 0.643-0.911; P=0.0021). Results for PFS by BICR were similar (median 15.4 vs 11.8months; HR=0.802, 95% CI: 0.678-0.949; P=0.0084). Progression events were recorded later by INV in 23% of pazopanib-treated patients and 17% of placebo-treated patients. The overall concordance between INV and BICR assessments was 84% and 86% in the pazopanib and placebo arms, respectively.

CONCLUSIONS:
By INV and BICR assessments, maintenance therapy with pazopanib in AEOC provided a significantly longer PFS than placebo. The good overall concordance between INV and BICR assessments, as well as HR and P value consistency, supports the reliability of investigator-assessed PFS as the primary endpoint in AGO-OVAR16.

 

Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.

 

 

2014

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Glasspool RM1, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA.

Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9. doi: 10.1097/IGC.0000000000000209.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Harter P1, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.

Since the early 1970s, the World Health Organization and the International Federation of Gynecology and Obstetrics have classified borderline ovarian tumors as an independent group of ovarian epithelial tumors. A consensus statement of the Gynecologic Cancer Intergroup is reported.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

Friedlander ML1, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P.

Mullerian adenosarcomas of the female genital tract are rare malignancies, originally described in the uterus, the most common site of origin, but they may also arise in extrauterine locations. Uterine adenosarcomas make up 5% of uterine sarcomas and tend to occur in postmenopausal women. They are usually low-grade tumors and are characterized by a benign epithelial component with a malignant mesenchymal component, which is typically a low-grade endometrial stromal sarcoma but can also be a high-grade sarcoma. Tumors that exhibit a high-grade sarcomatous overgrowth have a worse outcome. Adenosarcomas have been described as being midway along the spectrum between benign adenofibromas and carcinosarcomas. They generally have a good prognosis with the exception of deeply invasive tumors or those with high-grade sarcomatous overgrowth. Extrauterine adenosarcomas also have a higher risk for recurrence. In view of their rarity, there have not been any clinical trials in mullerian adenosarcomas and relatively little research. This article reviews the current knowledge and provides recommendation for the management of mullerian adenosarcomas.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S78-82. doi: 10.1097/IGC.0000000000000239.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.

Pautier P1, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I.

High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do not resemble proliferative-phase endometrial stroma. High-grade undifferentiated sarcomas are characterized by aggressive behavior and poor prognosis. Cyclin D1 has been reported as a diagnostic immunomarker for high-grade endometrial stromal sarcoma with an YWHAE-FAM22 rearrangement. YWHAE-FAM22 endometrial stromal sarcomas (ESS) represent a clinically aggressive subtype of ESS classified as high-grade endometrial sarcomas, and its distinction from the usual low-grade ESS with JAZF1 rearrangement and from HGUS with no identifiable molecular aberration may be important in guiding clinical management. Median age of the patients is between 55 and 60 years. The most common symptoms are vaginal bleeding, abdominal pain, and increasing abdominal girth.Disease is usually advanced with approximately 70% of the patients staged III to IV according to the International Federation of Gynecology and Obstetrics classification. Preferential metastatic locations include peritoneum, lungs, intra-abdominal lymph nodes, and bone. Median progression-free survival ranged from 7 to 10 months, and median overall survival ranged from 11 to 23 months. There is no clear prognostic factor identified for HGUS, not even stage. The standard management for HGUS consists of total hysterectomy and bilateral salpingo-oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy, have to be discussed in multidisciplinary staff meetings.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7. doi: 10.1097/IGC.0000000000000281.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Reed NS1, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors, but over the past 30 years, there have been a number of small series or anecdotal case reports on ovarian NETs. Neuroendocrine tumors in the gynecologic tract are uncommon and account for about 2% of all gynecologic malignancies but may also be metastatic from other sites. They require a multimodality therapeutic approach determined by the extent of disease and the primary organ of involvement. Pathological diagnosis is critical to guide therapy. Surgery is the cornerstone of treatment for localized disease. There have been many new developments for treatment of advanced NETs including somatostatin analogs, hepatic artery embolization, chemotherapy, interferons, mammalian target of rapamycin inhibitors and radiolabeled somatostatin analogs. Given the rarity and lack of level I evidence, this is by nature more of a guidance and recommendation for management of these rare tumors until we can mount international studies.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.

Leitao MM Jr1, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, Åvall-Lundqvist E, Kim K, Freyer G.

Vulvovaginal melanomas are rare tumors that account for a small fraction of all vulvovaginal cancers. Biologically, they seem to be similar to mucosal and acral melanomas of other sites. There are limited data specific to vulvovaginal melanomas, especially regarding systemic therapies. Most treatment decisions are based on extrapolation from data regarding cutaneous melanomas of other sites. It is reasonable to follow already established guidelines from other professional groups and societies. Outcomes tend to be worse compared with cutaneous melanomas likely because of the later presentation and physical biological characteristics of these tumors.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S117-22. doi: 10.1097/IGC.0000000000000198.

 

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

Mangili G1, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ.

OBJECTIVE:
The objective of this study was to provide a consensus review on gestational trophoblastic disease diagnosis and management from the combined International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

METHODS:
A joint committee representing various groups reviewed the literature obtained from PubMed searches.

RESULTS AND CONCLUSIONS:
Guidelines were constructed on the basis of literature review. After initial diagnosis in local centers, centralization of pathology review and ongoing care is recommended to achieve the best outcomes.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16. doi: 10.1097/IGC.0000000000000294.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.

Fujiwara H1, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K.

Cervical adenocarcinoma is known to be less common than squamous cell carcinoma of the cervix comprising approximately 25% of all cervical carcinomas. Differences in associated human papillomavirus types, patterns of spread, and prognosis call for treatments that are not always like those for squamous cancers. In this review, we report a consensus developed by the Gynecologic Cancer InterGroup surrounding cervical adenocarcinoma for epidemiology, pathology, treatment, and unanswered questions. Prospective clinical trials are needed to help develop treatment guidelines.

nt J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101. doi: 10.1097/IGC.0000000000000263.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

Hasegawa K1, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K.

Clear cell carcinomas of the uterine corpus and cervix are rare gynecological cancers with limited information regarding the pathogenesis and biology. At present, the approach to management is the same as for patients with the more common histological subtypes of endometrioid endometrial cancer and adenocarcinoma of the cervix. Surgical resection is the standard treatment for patients with early-stage disease, but there is no evidence-based approach to direct the management of patients with more advanced-stage disease at presentation or with recurrent disease. We review the epidemiology, pathology, and what is known about both uterine corpus and cervical clear cell cancers and make management recommendations.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297.

  

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S1, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

OBJECTIVES:
Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.

METHODS:
As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.

RESULTS:
Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53 mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.

CONCLUSIONS:
Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy


Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264.

  

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.

Amant F1, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.

Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S67-72. doi: 10.1097/IGC.0000000000000205.

 

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Hensley ML1, Barrette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I.

OBJECTIVES:
The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management.

METHODS:
Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made.

RESULTS:
The approach to management of uterine and ovarian leiomyosarcoma management is reviewed.

CONCLUSIONS:
Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.


Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261.

 

 

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Berton-Rigaud D1, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I.

Carcinosarcomas (also known as malignant mixed müllerian tumors) are rare and highly aggressive epithelial malignancies that contain both malignant sarcomatous and carcinomatous elements. Uterine carcinosarcomas (UCs) are uncommon with approximately more than 35% presenting with extra uterine disease at diagnosis. Up to 90% ovarian carcinosarcomas (OCs) will have disease that has spread beyond the ovary. Prognosis for localized stage disease is poor with a high risk of recurrences, both local and distant, occurring within 1 year. The survival of women with advanced UC or OC is worse than survival of endometrioid or high-grade serous histologies. No improvement in survival rates has been observed in the past few decades with an overall median survival of less than 2 years. Currently, there is no clear evidence to establish consensus guidelines for therapeutic management of carcinosarcomas. Until recently, gynecological carcinosarcomas were considered as a subtype of sarcoma and treated as such. However, carcinosarcomas are now known to be metaplastic carcinomas and so should be treated as endometrial or ovarian high-risk carcinomas, despite the lack of specific data. For UCs, a comprehensive approach to management is recommended with complete surgical staging followed by systemic chemotherapy in patients with both early and advanced stage disease. Active agents include paraplatin, cisplatin, ifosfamide, and paclitaxel. The combination of carboplatin-paclitaxel is the most commonly used regimen in the adjuvant and advanced setting. Adjuvant radiotherapy (external beam irradiation and/or vaginal brachytherapy) has not shown any overall survival benefit but has been reported to decrease local recurrences. For OCs and for other ovarian epithelial cancer, the mainstay of treatment remains cytoreductive surgical effort followed, even in early stage, by platinum-based chemotherapy, usually carboplatin-paclitaxel

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228.

 

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Brown J1, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.

Most women diagnosed with malignant ovarian germ cell tumors have curable disease and experience excellent survival with manageable treatment-associated morbidity, related both to tumor biology and improvements in treatment over the last 4 decades. Malignant ovarian germ cell tumors occur predominantly in girls, adolescents, and young women and are often unilateral tumors of early stage, although advanced-stage disease occurs in approximately 30% of patients. Tumors are usually chemosensitive, thereby allowing fertility-sparing surgery in most women with high chance of cure. Differences in practice do exist among providers in various subspecialties and geographic areas. In most settings, collaborative efforts among specialties allow the optimal treatment of women with these rare tumors, and implementation of standard guidelines at an international level should translate to effective clinical trial design, rapid accrual to clinical trials, and universally improved patient outcomes. This consensus guideline represents a summary of recommendations for diagnosis and management that has been agreed upon by cooperative groups worldwide. It builds upon individual publications including previously published summary documents and provides the most current practice standards validated worldwide.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I1, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249.

 

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serouscarcinomas.

Gourley C1, Farley JProvencher DMPignata SMileshkin LHarter PMaenpaa JKim JWPujaide-Lauraine EGlasspool RMRay-Coquard IGershenson D.

Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes (high-grade serous, clear cell, endometrioid, and mucinous). In particular, it differs from high-grade serous ovariancancer in that it presents at a much younger age, is more indolent, and is relatively chemoresistant. Very few clinical trials have been performed exclusively in this tumor type; and as such, specific data guiding optimal management are limited

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-13. doi: 10.1097/IGC.0000000000000257.

See comment in PubMed Commons below

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Okamoto A1, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzazanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.

Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289.

 

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois A1, Floquet A2, Kim JW2, Rau J2, Del Campo JM2, Friedlander M2, Pignata S2, Fujiwara K2, Vergote I2, Colombo N2, Mirza MR2, Monk BJ2, Kimmig R2, Ray-Coquard I2, Zang R2, Diaz-Padilla I2, Baumann KH2, Mouret-Reynier MA2, Kim JH2, Kurzeder C2, Lesoin A2, Vasey P2, Marth C2, Canzler U2, Scambia G2, Shimada M2, Calvert P2, Pujade-Lauraine E2, Kim BG2, Herzog TJ2, Mitrica I2, Schade-Brittinger C2, Wang Q2, Crescenzo R2, Harter P2

J Clin Oncol. 2014 Sep 15. pii: JCO.2014.55.7348.


Shall we settle for low-level evidence?
Mirza MR
J Gynecol
Oncol. 2014 Jul;25(3):162-163. English.

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer.
Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E.
J Clin Oncol. 2014 Mar 31. [Epub ahead of print] PMID: 24687829 [PubMed - as supplied by publisher]

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.
J Clin Oncol. 2014 Mar 17. [Epub ahead of print] PMID: 24637997 [PubMed - as supplied by publisher]
Related citations


Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B.
BMC Cancer. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68.PMID: 24498853 [PubMed - in process] Free PMC Article
Related citations


2013
Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era.
Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting.
Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb. PMID: 24257568 [PubMed - in process] Related citations


Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A; member trial groups of the European Network of Gynaecological Trial groups (ENGOT). Int J Gynecol Cancer. 2013 Sep;23(7):1339-43. doi: 10.1097/IGC.0b013e31829b87da. PMID: 23970159 [PubMed - indexed for MEDLINE] Related citations


The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A. Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013. Epub 2013 May 18


A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie- Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. Ann Oncol. 2013 Apr;24(4):937-43. doi: 10.1093/annonc/mds538. Epub 2012 Oct 26.


Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T.
Lancet Oncol. 2013 Mar;14(3):236-43. doi: 10.1016/S1470-2045(12)70567-3. Epub 2013 Jan 18


2012
First line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC vs. TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
K. Lindemann1, R.D. Christensen2, I. Vergote3, G.Stuart4, M.A. Izquierdo5, J Kern1, H. Havsteen6, E. Eisenhauer7, M. Ridderheim8, A.B. Lopez9, H. Hirte10, E. Aavall-Lundquvist11, E. Vrdoljak12, J. Green13 and G.B. Kristensen1,14Ann Oncol. 2012 Oct;23(10):2613-9. Epub 2012 Apr 26.http://www.ncbi.nlm.nih.gov/pubmed/?term=22999502


Cancer of the corpus uteri.
Amant F, Mirza MR, Creutzberg CL. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S110-7. doi: 10.1016/S0020-7292(12)60024-1. No abstract available. PMID: 22999502 [PubMed - indexed for MEDLINE] Related citations.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26


Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.Annals of Oncology 23: 1185–1189, 2012 May


CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E.
Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12


Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial
Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Ann Oncol. 2012 Jan 30. [Epub ahead of print]


A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284. PMID: 22204725 [PubMed - indexed for MEDLINE] Free Article Related citations


2011
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; on behalf of Gynecologic Cancer Intergroup. Ann Oncol. 2011 Nov;22(11):2417-2423. Epub 2011 Mar 14.


Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Brøsen K. Basic Clin Pharmacol Toxicol. 2011 Sep 28. doi: 10.1111/j.1742-7843.2011.00802.x. [Epub ahead of print] PMID: 21955855 [PubMed - as supplied by publisher] Related citations


Prognostic nomogram to predict progression-free survival in patients with platinum- sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13.


Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, ReinthallerA, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E. Gynecol Oncol. 2011 Aug;122(2):226-32. Epub 2011 May 14.


Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B,Boman K, Park YC, Parekh T, Lebedinsky C, Gómez J, Monk BJ. Gynecol Oncol. 2011 Aug;122(2):350-5. Epub 2011 May 5.

Subspecialist training in surgical gynecologic oncology in the Nordic countries.
Antonsen SL, Avall-Lundqvist E, Salvesen HB, Auranen A, Salvarsdottir A, Høgdall C; Nordic Society of Gynaecological Oncology. Acta Obstet Gynecol Scand. 2011 Aug;90(8):917-20.

Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.Br J Cancer. 2011 Jul 26;105(3):360-5.


Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C.Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi: 10.1007/s00228-011-1007-6. Epub 2011 Feb 16. PMID: 21327421 [PubMed - indexed for MEDLINE] Related citations


Clinical trials in recurrent ovarian cancer.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):771-5.


First-Line Therapy in Ovarian Cancer Trials.
Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; on behalf of the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):756-762.


Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6. PMID: 20368717 [PubMed - indexed for MEDLINE] Related citations


Definitions for Response and Progression in Ovarian Cancer Clinical Trials IncorporatingRECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A,Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. Int J Gynecol Cancer. 2011 Feb;21(2):419-423

 

2010
The value of gynecologic cancer follow-up: evidence-based ignorance? Lajer H, Jensen MB, Kilsmark J, Albæk J, Svane D, Mirza MR, Geertsen PF, Reerman D, Hansen K, Milter MC, Mogensen O.
Int J Gynecol Cancer. 2010 Nov;20(8):1307-20. doi: 10.1111/IGC.0b013e3181f3bee0. Review. PMID: 21051970 [PubMed - indexed for MEDLINE] Related citations

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR, Lund B, Lindegaard JC, Keldsen N, Mellemgaard A, Christensen RD, Bertelsen K. Gynecol Oncol. 2010 Oct;119(1):26-31. doi: 10.1016/j.ygyno.2010.06.022. Epub 2010 Jul 17. PMID: 20638711 [PubMed - indexed for MEDLINE] Related citations


Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-Results from two randomised studies.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Eur J Cancer. 2010 Sep;46(13):2422-31


Addition of gemcitabine as third drug to carboplatin-paclitaxel in firstline treatment of epithelial ovarian cancer. A prospectively randomized Gynecologic Cancer Intergroup (GCIG) Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), and the Nordic Society of Gynecologic Oncology (NSGO).

Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, Hans-Helge Müller, Philipp Harter, Gunnar Kristensen, Florence Joly, Jens Huober, Elisabeth Åvall-Lundqvist, Béatrice Weber, Christian Kurzeder, Svetislav Jelic, Eric Pujade-Lauraine, Alexander Burges, Jacobus Pfisterer, Martina Gropp, Anne Staehle, Pauline Wimberger, Christian Jackisch, Barbara Schmalfeldt, Antje-Kristina Belau, Sibylle Loibl, Kerstin Wollschlaeger, Jalid Sehouli. J Clin Oncol. 2010 Sep 20;28(27):4162-9


Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin for Patients with Platinum-Sensitive Ovarian Cancer in Late Relapse. Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar Kristensen, Christian Jackisch, Florence Joly-Lobbedez, Chris Brown, Nathalie Le Fur, and Andreas du Bois. J Clin Oncol 28:3323-3329, 2010 July 10

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Pharmaceutical Companies
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups. Int J Gynecol Cancer 2010 April 20: 476-478

 

2009
Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup (GCIG)
W. Small, A. Du Bois, S. Bhatnagar, N. Reed, S. Pignata, R. Pötter, D. M. Randall, M. R. Mirza, E. L. Trimble, K. Gaffney. Int. J. Gynecol Cancer, 2009 April; 19: 395-399.

Intravaginal brachytherapy in FIGO Stage I low-risk endometrial cancer – a controlled randomized study.
Sorbe B, Nordström B, Mäenpää J, Kuhelj J, Kuhelj D, Okkan S, Delalouye J-F, Frankendal B: Int J Gynecol Cancer 19: 873-878, 2009 July 19.


Endometrial cancer state of the science meeting
Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Int J Gynecol Cancer. 2009 Jan-Feb;19(1):134-40

Patterns of care for radiotherapy in vulvar cancer: A Gynecologic Cancer Intergroup, (GCIG) study.
D. K. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A. Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble. Int. J. Gynecol Cancer, 2009 Jan; 19: 163-7.


2007
Clinical trials in gynecological cancer.
Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT; Gynecologic Cancer Intergroup. Int J Gynecol Cancer. 2007 May-Jun;17(3):547-56

Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). D. K. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A. Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble. Int. J. of Radiation OncologyBiologyPhysics, 2007 June 1; 68: 485-490


2006
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart J, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. J Clin Oncol. 2006 Jan 1;24(1):45-51


2005
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pre-treated with platinum-taxane: Results from a multicenter Phase I/II study.
Gronlund B, Engelholm SA, Horvath G, Mäenpää J, Ridderheim M. Cancer 103: 1388-1396, 2005 april.

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC.
Bois A, Sehouli J, Lund B, Joly F, Huober J, Jensen TS, Levy E, Heilmann V, Boman K, Hardy-Bessard AC, Burges A, Mäenpää J, et al.. Int J Gynecol Cancer 15: Suppl 3: 224-225, 2005.


First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival.
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Baekelandt M, Lopez AB, Hirte H, Aavall-Lundqvist E, Lorenz E, Cerar O. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:221.

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.
Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I. Ann Oncol. 2005 Oct;16 Suppl 8:viii13-viii19


2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
duBois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade- Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. Ann Oncol. 2005;16 Suppl 8:viii7-viii12.


3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US. Ann Oncol. 2005;16 Suppl 8:viii36-viii38.

History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.
Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J. Ann Oncol. 2005;16 Suppl 8:viii5-viii6.

The Gynecologic Cancer Intergroup (GCIG): history and current status.
Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M; GCIG; AGO-OVAR; ANZGOG; EORTC-GCC; GEICO; GINECO; GOG; JGOG; MRC; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG. Ann Oncol. 2005;16 Suppl 8:viii39-viii42

Integration of new or experimental treatment options and new approaches to clinical trials.
Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U; ANZGOG; AGO-OVAR; NSGO; GOG; EORTC; GEICO; MRC/NCRI; NCIC-CTG; IGCS; GINECO; NCI-US; SGCTG. Ann Oncol. 2005;16 Suppl 8:viii30-viii35


2004
New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. J Natl Cancer Inst. 2004 Mar 17;96(6):487-8.


2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8.

First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin.
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:172-7. PMID: 14656276 [PubMed - indexed for MEDLINE] Related citations


2002
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. The International Collaborative Ovarian Neoplasms (ICON) Group. Lancet 360:505-515, 2002

Attitudes towards clinical research amongst participants and nonparticipants.
Madsen SM, Mirza MR, Holm S, Hilsted KL, Kampmann K, Riis P. J Intern Med. 2002 Feb;251(2):156-68. PMID: 11905591 [PubMed - indexed for MEDLINE] Related citations


2001
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen , Trope CG. Lancet. 2001 Jan 20;357(9251):176-82.


2000
New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB. J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5.

Randomized study on adjuvant chemotherapy in stage I high risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.
Tropé C., Kaern J., Hogberg T., Abeler V., Hagen B., Kristensen G., Onsrud M., Pettersen E., Rosenberg P., Sandvei R., Sunfor K. And Vergote I. Annals of Oncology 11, 281-288, 2000

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope CG, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. J Natl Cancer Inst. 2000 May 3;92(9):699-708.

Epithelial ovarian cancer (advanced stage): consensus conference (1998).
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB, Willemse PH. Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83.

1999
Advanced epithelial ovarian cancer: 1998 consensus statements
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al. Ann Oncol. 1999;10 Suppl 1:87-92


Intergroup collaboration in ovarian cancer: a giant step forward.
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C, Swenerton K, Harper P, Vermorken JB. Ann Oncol. 1999;10 Suppl 1:83-6.

1997
Suramin in non-small cell lung cancer and advanced breast cancer.
Two parallel phase II studies. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Acta Oncol. 1997;36(2):171-4. PMID: 9140434 [PubMed - indexed for MEDLINE] Related citations


1996
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Sundfor K, Trope CG, Hogberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg R. Cancer. 1996 Jun 1;77(11):2371-8.

1994
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Jakobsen P, Sørensen B, Bastholt L, Mirza MR, Gjedde SB, Mouridsen HT, Rose C. Cancer Chemother Pharmacol. 1994;35(1):45-52. PMID: 7987976 [PubMed - indexed for MEDLINE] Related citations


The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Sørensen B, Bastholt L, Mirza MR, Gjedde SB, Jakobsen P, Mouridsen HT, Rose C. Cancer Chemother Pharmacol. 1994;34(5):439-43. PMID: 8070013 [PubMed - indexed for MEDLINE] Related citations


1992
The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma. Mirza MR, Brincker H, Specht L. Crit Rev Oncol Hematol. 1992;12(3):217-29. Review. No abstract available. PMID: 1497822 [PubMed - indexed for MEDLINE] Related citations


1991
Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients.
Mirza MR. Cancer Treat Rev. 1991 Jun;18(2):145-8. Review. PMID: 1804525 [PubMed - indexed for MEDLINE] Related citations

MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Mirza MR, Brincker H. Acta Oncol. 1991;30(1):17-21. PMID: 2009179 [PubMed - indexed for MEDLINE] Related citations

Submitted:

Published abstracts

2008:
G. B. Kristensen, J. Kaern, M. Baekelandt, T. Skeie-Jensen, R. dePont Christensen, E. Åvall- Lundqvist, M. Bergdahl, R. Sandvei, T. Hoegberg, S. Grenman
Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer- a NSGO study (NSGO-OC-0101)
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings Part I. Vol 26, No. 15S, (May 20,2008). Abstract #5508

2007:
T. Hogberg, P. Rosenberg, G. Kristensen, CF de Oliviera, R dePont Christensen, B Sorbe, C Lundgren, H Andersson, T Salmi, NF Reed.
A randomized phase-III study on adjuvant treatment with radiation (RT) 177; chemotherapy (CT)
in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991).
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5503. Abstract #5503

2006:
Britta Nordström, Tuula Salmi, Mansoor R Mirza, Vera Abeler and Gunnar Kristensen
Exemestane in advanced and recurrent endometrial carcinoma. A phase II study. J Clin Oncol 2006;24,18S:266, abstract #5042

2004:
Kristensen GB et al.
First Line Treatment of Ovarian Cancer: Paclitaxel/Epirubicin/Carboplatin (TEC) versus Paclitaxel/Carboplatin (TC). Report on progression free survival
Proc Am Soc Clin Oncol abst # 5003. 2004. I. Vergote, G. Kristensen, G. Stuart, J.M. del Campo J. Kærn, M. Baekelandt, A.B Lopez, H. Hirte, E. Aavall-Lundquist, E. Lorenz, O. Cerar
First line treatment of ovarian/tubal/peritoneal cancer figo stage IIb-IV with paclitaxel/ carboplatin with or without epirubicin (TEC vs TC).
A gynecologic cancer intergroup study of the NSGO, EORTC-GCG, and NCIC-GCG. Results on progression free survival.
International Journal of Gynecological Cancer Suppl 1, 2004. Abst#007

2002:
Kristensen G, Vergote IV, Stuart G, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol abst # 805. 2002. Vergote I, Kristensen G, Stuart G, Aaval-Lundquist E, Kaern J, Eisenhauer E. First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial. Int J Gynecol Cancer. 12(5): 521 (abstract # OV007), 2002

Communications:

2010:
Eric Pujade-Lauraine on behalf of all GCIG collaborators CALYPSO trial. Carboplatin & Pegylated Liposomal Doxorubicin (PLD)versus Carboplatin & Paclitaxel in Relapsed, Platinum-sensitive Ovarian Cancer Oral presentation at 2010 ASCO Annual Meeting
Tim Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark Carey, Philip Beale, Andreas Cervantes, Amit Oza on behalf of GCIG ICON7 collaborators Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Oral presentation at 2010 ASCO Annual Meeting Paul Vasey on behalf of all GCIG ICON7 collaborators Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Oral presentation at 2010 ESMO Meeting 
Mark Heywood on behalf of all GCIG ICON7 collaborators.
Results of ICON7: A phase III randomised two-arm Gynaecologic Cancer InterGroup (GCIG) trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC).
Oral presentation at 2010 ESMO Meeting


2009:
Jørn Herrstedt, Huober, Franck Priou, Stats, NSGO, Kurzeder, Jacob Pfisterer, Stähle, I Ray- Coquard, Andreas du Bois2 (PI). for the GCIG Intergroup of), NSGO (Scandinavia), AGO-OVAR (Germany) and GINECO (France ). A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine- paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OS): survival of FIGO stage I-IIA patients
Oral presentation at 2009 ASCO Annual Meeting

2008:
G. B. Kristensen, J. Kaern, M. Baekelandt, T. Skeie-Jensen, R. dePont Christensen, E. Åvall- Lundqvist, M. Bergdahl, R. Sandvei, T. Hoegberg, S. Grenman. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer- a NSGO study (NSGO-OC-0101)
Oral presentation at 2008 ASCO Annual Meeting.
G. Kristensen, J. Kaern, E. Åvall-Lundqvist, R. Christensen, S. Grenmann, M. Bergdahl, R. Sandvei, M. Baekelandt, T. Skeie-Jensen, M. Kalling, T. Hoegberg
CHEMOTHERAPY VERSUS HORMONAL TREATMENT IN PATIENTS WITH PLATINUM AND TAXANE RESISTANT OVARIAN CANCER - A NSGO STUDY
IGCS 12.th Biennial Meeting, 2008 Bangkok, Thailand
A. du Bois, G. Kristensen, F. Joly, H.-H. Müller, A. Belau, E. Avall-Lundqvist, B. Weber, L. Hanker, J. Lindegaard, E. Levy, H.-J. Lück, K. Wollschlaeger, U. Canzler, W. Schröder, J. Sehouli, J. Huober
RANDOMIZED PHASE-III GCIG STUDY (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): GEMCITABINE-PACLITAXEL-CARBOPLATIN (TCG) VS. PACLITAXEL-CARBOPLATIN (TC) AS FIRST-LINE TREATMENT OF OVARIAN CANCER (OC)
IGCS 12.th Biennial Meeting, 2008 Bangkok, Thailand

2007:
T. Hogberg, P. Rosenberg, G. Kristensen, CF de Oliviera, R dePont Christensen, B Sorbe, C Lundgren, H Andersson, T Salmi, NF Reed. A randomized phase-III study on adjuvant treatment with radiation (RT) 177; chemotherapy (CT)
in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). Oral presentation at 2007 ASCO Annual Meeting. GB. Kristensen, I. Vergote, G. Stuart, J.M. del Campo, J. Kærn, M. Baekelandt, A.B. Lopez, H. Hirte, E. Aavall-Lundqvist, E. Lorenz & O. Cerar. First-line treatment of ovarian/tubal/peritoneal cancer figo stage IIb–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCI-C CTG. Results on overall survival.
Poster at ESGO15, Berlin, 2007
B. Nordstrom, M. Mirza, Rene dePont Christensen, H. Oksefjell, G. Kristensen;
Exemestane in advanced and recurrent endometrial carcinoma.
A phase II study by NSGO Poster at ESGO15, Berlin, 2007
M. Baekelandt, J. Herrstedt, R dePont Christensen, J. Kærn, B. Lund, M. Mirza, T. Skeie Jensen, J. Mäenpää, E. Lindegaard Madsen, G.B. Kristensen

A Nordic Society of Gynecological Oncology (NSGO) multicenter, non-randomized phase II study of docetaxel and carboplatin as second line chemotherapy in patients with first relapse of
platinum-sensitive epithelial ovarian, peritoneal or fallopian tube cancer
Poster at ESGO15, Berlin, 2007

2006:
Britta Nordström, Tuula Salmi,Mansoor R Mirza, Vera Abeler and Gunnar Kristensen
Exemestane in advanced and recurrent endometrial carcinoma. A phase II study.
Poster ASCO Atlanta, USA, 2006

2002:
Kristensen G, Vergote IV, Stuart G, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.
Am Soc Clin Oncol 2002
Stuart G, Kristensen G, Vergote IV, Izquerdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.
Consensus statements/reviews:

1999:
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10 Suppl 1:87-92
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C, Swenerton K, Harper P, Vermorken JB.
Intergroup collaboration in ovarian cancer: a giant step forward. Ann Oncol. 1999;10 Suppl 1:83-6.

1993:
Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink W, van der Burg ME, Calvert AH, Conte PF, Dauplat J, et al
Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol. 1993;4 Suppl 4:83-8.